Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly subcutaneous NNC0662-0419 dose-finding study in adults with type 2 diabetes
2025-523260-20-00Phase 2Authorised
- Sponsor
- Novo Nordisk
- Start
- Apr 2026
- Modality
- Peptides
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of NNC0662-0419 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c. Planned start Apr 2026; status: authorised.
02
Drugs
NNC0662-0419
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2025-523260-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523260-20-00.